It is not a dietary supplement, drug, or cosmetic and is not intended for human or animal consumption
Medical professionals should equip and discuss this information and safety profile with patients, allowing them to understand the treatment, its potential risks, and benefits to make informed healthcare decisions
By restoring this master antioxidant, patients may experience improvements across multiple physiological systems
The impact of dosing frequency is evident in persistence data: weekly semaglutide (Ozempic) keeps patients on treatment for a median of 279 days, compared to just 120 days for daily liraglutide (Saxenda)
[DOI] [PMC free article] [PubMed] 95.Koros C, Simitsi AM, Papagiannakis N, et al